Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol 2007 Feb;102(2):449-51
Date
11/15/2006Pubmed ID
17100972DOI
10.1111/j.1572-0241.2006.00937.xScopus ID
2-s2.0-33846547897 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
A 48-yr-old man with acute myeloid leukemia (AML) required urgent allogeneic hematopoietic stem cell transplantation because of failed attempts to induce remission via chemotherapy. He had an HLA identical donor sister who was hepatitis C virus (HCV) RNA positive. In order to prevent HCV transmission to her brother, the donor was treated with weekly injections of pegylated interferon alfa-2b (150 mug subcutaneously every week) and daily ribavirin (1 g/day) for 5 wk at which time her qualitative polymerase chain reaction (PCR) was negative. Her stem cells were successfully grafted into the recipient. The recipient remained HCV PCR negative after transplant until death from relapsed AML.
Author List
Surapaneni SN, Hari P, Knox J, Daniel J, Saeian KAuthors
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of WisconsinKia Saeian MD Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Administration, OralAntiviral Agents
Disease Transmission, Infectious
Drug Therapy, Combination
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hepacivirus
Hepatitis C
Humans
Injections, Subcutaneous
Interferon-alpha
Leukemia, Myeloid, Acute
Male
Middle Aged
Polyethylene Glycols
Polymerase Chain Reaction
RNA, Viral
Recombinant Proteins
Ribavirin
Transplantation, Homologous
